Hemas Holdings PLC (HHL) and its subsidiaries achieved consolidated revenues of Rs.37.9 bn, a year-on-year (YoY) growth of 16.9% for the twelve months ended March 31, 2016.
During this period operating profit reached Rs.4 bn and earnings Rs.2.7 bn, growth of 17.5% and 37.7% respectively. An additional interest income of Rs.280 mn was earned from investing the proceeds of the rights issue.
The FMCG sector achieved total revenues of Rs.14.3 bn for the twelve months, a 20.2% YoY increase over the previous financial year. Operating profits were Rs.1.8 bn, 50.5% YoY growth, whilst earnings grew at 37.2% to stand at Rs.1.4 bn. Strong performance was underpinned by our Bangladesh operation maintaining excellent revenue and profit growth, as well as strong sales across all our major brands in the domestic market and relatively weak commodity prices for key raw material inputs. Overall healthcare sector revenue for the twelve months under review stood at Rs.16.1 bn, a YoY increase of 16.0%, whilst earnings grew at 22.8%. During the year, Hemas Hospitals opened its first wellness centre at Orion City, three new laboratories and invested in building capabilities in the Urology specialty. Our hospitals growth in revenue contributed 34.7% of the overall segment’s revenue growth. Hemas pharmaceutical distribution operation registered a YoY topline growth of 8.2% maintaining its market leadership position. Our pharmaceutical sales growth continues to be driven by our strong presence in growing therapeutic segments.
JL Morison posted a YoY growth of 22.8% and earnings growth of 43.4% for the twelve months ended March 31, 2016. Revenue growth was largely driven by the increase in sales from the buyback arrangement with Government of Sri Lanka and sales growth in key diagnostics agencies.
The significant growth in operating profit resulted from increases in revenues in both consumer/OTC products and pharmaceutical segments, efficiency and capacity gains at the plant after a period of closure of the plant in Q1 2014/15 and a restructured distribution network. Transportation sector reported a revenue of Rs.1.8Bn, a 17.2% YoY topline growth. Revenue growth was driven by higher volumes through our domestic logistics operation with warehouses operating at high levels of capacity, higher volume throughput at our container depot and new 3PL customers,
www.dailynews,lk
During this period operating profit reached Rs.4 bn and earnings Rs.2.7 bn, growth of 17.5% and 37.7% respectively. An additional interest income of Rs.280 mn was earned from investing the proceeds of the rights issue.
The FMCG sector achieved total revenues of Rs.14.3 bn for the twelve months, a 20.2% YoY increase over the previous financial year. Operating profits were Rs.1.8 bn, 50.5% YoY growth, whilst earnings grew at 37.2% to stand at Rs.1.4 bn. Strong performance was underpinned by our Bangladesh operation maintaining excellent revenue and profit growth, as well as strong sales across all our major brands in the domestic market and relatively weak commodity prices for key raw material inputs. Overall healthcare sector revenue for the twelve months under review stood at Rs.16.1 bn, a YoY increase of 16.0%, whilst earnings grew at 22.8%. During the year, Hemas Hospitals opened its first wellness centre at Orion City, three new laboratories and invested in building capabilities in the Urology specialty. Our hospitals growth in revenue contributed 34.7% of the overall segment’s revenue growth. Hemas pharmaceutical distribution operation registered a YoY topline growth of 8.2% maintaining its market leadership position. Our pharmaceutical sales growth continues to be driven by our strong presence in growing therapeutic segments.
JL Morison posted a YoY growth of 22.8% and earnings growth of 43.4% for the twelve months ended March 31, 2016. Revenue growth was largely driven by the increase in sales from the buyback arrangement with Government of Sri Lanka and sales growth in key diagnostics agencies.
The significant growth in operating profit resulted from increases in revenues in both consumer/OTC products and pharmaceutical segments, efficiency and capacity gains at the plant after a period of closure of the plant in Q1 2014/15 and a restructured distribution network. Transportation sector reported a revenue of Rs.1.8Bn, a 17.2% YoY topline growth. Revenue growth was driven by higher volumes through our domestic logistics operation with warehouses operating at high levels of capacity, higher volume throughput at our container depot and new 3PL customers,
www.dailynews,lk
No comments:
Post a Comment